Palisade Bio (NASDAQ:PALI – Get Free Report) is projected to issue its Q3 2026 resultson Monday, November 9th. Analysts expect Palisade Bio to announce earnings of ($0.06) per share and revenue of $0.47 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.
Palisade Bio (NASDAQ:PALI – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). The company had revenue of $0.50 million during the quarter, compared to the consensus estimate of $0.50 million. On average, analysts expect Palisade Bio to post ($0.22) EPS for the current fiscal year and ($0.28) EPS for the next fiscal year.
Palisade Bio Stock Performance
Shares of PALI stock opened at $1.16 on Monday. The stock has a market cap of $202.15 million, a price-to-earnings ratio of -2.42 and a beta of 1.61. The stock has a 50-day moving average of $1.65 and a 200-day moving average of $1.85. Palisade Bio has a 1-year low of $1.10 and a 1-year high of $2.85.
Wall Street Analyst Weigh In
Several research firms have issued reports on PALI. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Palisade Bio in a report on Tuesday, October 13th. Oppenheimer reaffirmed an “outperform” rating on shares of Palisade Bio in a research note on Wednesday, October 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a research note on Monday, October 12th. Raymond James Financial assumed coverage on Palisade Bio in a research report on Thursday, October 8th. They set an “outperform” rating and a $6.00 target price on the stock. Finally, Wall Street Zen downgraded Palisade Bio from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $9.29.
View Our Latest Research Report on Palisade Bio
Palisade Bio Company Profile
Palisade Bio, Inc (NASDAQ: PALI) is a clinical-stage biopharmaceutical company focused on developing therapies for gastrointestinal diseases and complications associated with gastrointestinal surgery. The company’s research is centered on treatments intended to protect the intestinal barrier and support recovery following major medical procedures.
Palisade Bio’s lead product candidate, LB1148, is an orally administered serine protease inhibitor designed to reduce the harmful effects of digestive enzymes released during surgery or gastrointestinal injury.
See Also
- Five stocks we like better than Palisade Bio
- Royal Caribbean Buys the Beach as Norwegian Fixes the Ship
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
